

Affidea Expands in Spain with the Acquisition of Tecma Clinic



The Company enters Valencia through the strategic acquisition of Tecma, a leading diagnostic imaging and outpatient care provider

- Affidea reaches 320 centers at European level, seeing over 10 million patients every year
- Tecma clinic is the leading private provider in Valencia region, offering diagnostic imaging, a wide range of outpatient services, dentistry and medical check-ups for driving, firearm and nautical license.
- Tecma acquisition is the 4th acquisition that the company completes in 2022 at European level and the third in Spain over the last year

Affidea Group announced today the acquisition of 100% of Tecma clinic, a renowned outpatient medical provider in Valencia. Through this acquisition, Affidea expand its business model by adding new outpatient capabilities.

Tecma clinic carries out more than 300.000 visits per year, offering advanced diagnostic imaging, a wide range of more than 20 medical consultations, laboratory tests, dentistry, medical check-ups related to driving, firearm and nautical license, rehabilitation and physiotherapy treatments. The company works with more than 200 health professionals, offering high quality medical care 365 days a year for public and private patients, PHIs and sport federations.

For 15 years, Tecma Clinic in Alzira (Valencia) has been an important and highly reputable healthcare provider, covering an area of 260,000 inhabitants, being recognized as a reference medical center for the needs of athletes and international sports associations.

With this acquisition, in Spain, Affidea will reach 37 centers, serving in total more than 500.000 patients every year, expanding its geographical footprint, with strengthened capacity in outpatient services that will allow Affidea to be one of the preferred healthcare providers for corporations and private health insurers. At country level, Affidea is working with close to a thousand professionals, out of which 200 are coming from Tecma clinic.

Giuseppe Recchi, CEO Affidea Group, stated: “Our strategy of expansion and developing our leadership position in every country is moving forward with yet another strategic acquisition. In the last year we grew significantly, adding 51 new medical centres to our network, reaching today more than 320 centers and an impressive range of outpatient services that allow us to better serve our patients, offering them one-stop-shops for their medical needs. The future of healthcare is around integrated outpatient pathways, having in mind the patients’ needs and market demands. At Affidea, we are proud that we managed to build a unique network of centers where the embedded outpatient services come to complement and create strong synergies with our core business of advanced diagnostics, always with patient experience in mind. This is what make us the preferred provider for patients, doctors and public and private payors. We are focused on strongly accelerating our growth, aiming to improve the access to high quality medical services for our patients”.

Theo Kravvas, Country Manager for Affidea Spain, mentioned: “Clinica Tecma in Alzira (Valencia) is a project highly aligned with our strategy of expansion in new geographic areas in Spain and with the enrichment of the clinical offer to patients and partners. We are very proud to include Clinica Tecma in our network. With this milestone, Affidea Spain is increasing its footprint in Valencia community with a clinic that is a leader in outpatient and diagnostic services in the region and sets the high standards that Affidea Spain offers in the market. We are delighted to welcome Clinica Tecma in the Affidea family!”.

Dr Jorge Candel, director of Tecma clinic, and a recognised professional with close links to sport, having been a doctor for the Spanish national football team, Valencia FC and an external consultant for Chelsea FC, added: "Following our growth ambitions, we are very pleased to join the international healthcare group Affidea as our strategic partner that will provide the necessary resources along with the healthcare experience. Each one of the 200 professionals that make up Clinica Tecma is committed to the new journey that will undoubtedly bring business stability and great expectations for the future. With this union, the future growth of the company takes off, in which we foresee significant improvements in the latest technologies, expansion in new service lines and state of art facilities, always with the goal of offering an outstanding patient and staff experience".

With this acquisition, at European level, Affidea's network reaches 320 centers, working with over 10.000 professionals and seeing almost 10 million patients every year. Affidea has a long-term track record in successfully adding and integrating 160 new centers in the last 5 years.

RSM Spain performed the financial due diligence and acted as Affidea's legal and tax advisor, while Valsalto performed the labour due diligence.

Affidea, expanding its business model, with a strong appetite for growth

Tecma clinic is the third acquisition that Affidea completes in Spain over last 12 months, after the addition of the outpatient provider Medicentro, in Madrid and demonstrates the continued commitment to the successful expansion of its business model. At European level, Affidea added more than 50 centers through acquisitions in the past year. In January 2022, Affidea announced the acquisition of Promea, a reputed outpatient healthcare provider in Italy, followed by an outpatient clinic in Lithuania and the most recent one in Switzerland, Brust Zentrum Zurich.

In **Spain**, Affidea performs more than 75.000 diagnostics examinations per month, seeing almost 500.000 patients every year. This new expansion in Spain comes after Medicentro and Clinica Gamma acquisitions in 2021, two medical providers added to enhance the company's outpatient care and nuclear medicine portfolio and to strengthen its position as a leading player of the private health sector in the market.

Source: [Affidea](#)

Published on : Mon, 6 Jun 2022